title: Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: a meta-analysis.
abstract: BACKGROUND
  A number of studies have investigated the relationship between fibroblast growth factor receptor1 (FGFR1) gene copy number and survival in non-small cell lung cancer (NSCLC) patients. However, conclusions reported by different parties seem to be inconsistent, especially regarding the differences among different histopathologic subtypes. To derive a more precise estimate of the prognostic significance of FGFR1 gene copy number, we have reviewed published studies and carried out a meta-analysis.
  
  
  METHODS
  The meta-analysis was conducted in accordance with PRISMA guidelines. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and an overall HR was calculated.
  
  
  RESULTS
  We identified 6 eligible studies, all dealing with NSCLC. The global quality score ranged 32.5-80%, with a median of 53.33%. For FGFR1 amplification in three studies including differed according to histological type, the overall RR was 0.86 which 95% confidence interval (CI) was 0.75 to 0.99 and P value was 0.048. Combined HR for the six evaluable studies was 1.17 (95% CI: 0.95 to 1.43). In the subgroup of squamous cell lung cancer (SQCC), the combined HR was 1.24 (95% CI: 0.89 to 1.73). For the Asian populations' studies, the combined HR was 1.67 (95% CI: 1.1 to 2.52).
  
  
  CONCLUSIONS
  FGFR1 amplification significantly was more frequent in SQCC. FGFR1 was not associated with poorer survival in patients with NSCLC. Furthermore studies will be needed in terms of survival implications.
authors: 1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
authors: Wen
authors: W
authors: Yang
authors: 1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
authors: Yan-Wen
authors: YW
authors: Yao
authors: 1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
authors: Jun-Li
authors: JL
authors: Zeng
authors: 1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
authors: Wen-Jun
authors: WJ
authors: Liang
authors: 1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
authors: Li
authors: L
authors: Wang
authors: 1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
authors: Cui-Qing
authors: CQ
authors: Bai
authors: 1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
authors: Chun-Hua
authors: CH
authors: Liu
authors: 1 Department of Respiratory Medicine, Jinling Hospital, Nanjing University, School of Medicine, Nanjing 210002, China ; 2 Southern Medical University, Guangzhou 510515, China.
authors: Yong
authors: Y
authors: Song
keywords: Lung cancer; fibroblast growth factor receptor1 (FGFR1); meta-analysis; prognosis; survival; systemic review